Good news for human embryonic stem cell therapeutics- BlueRock received "fast track" designation for dopamine neurons derived from human embryonic stem cells for treatment of Parkinson's disease.
Good news for human embryonic stem cell t... - Cure Parkinson's
Good news for human embryonic stem cell therapeutics- BlueRock received "fast track" designation for dopamine neurones
I would like to hear the opinions of those familiar with the workings of the FDA about this fast tracking. How will this precedent effect other stem cell trials?
Though this study is fast-tracked it does not mean that other stem cell trials will not be fast-tracked while the BlueRock trial is being conducted - they should be considered individually. However, if results are positive for the primary objective of the BlueRock Phase 1 trial (safety and tolerability of stem cells one year post transplant - estimated completion in Jan 2023) then it could be easier for other stem cell trials/therapies to gain fast-track status.
It also looks like company leadership at BlueRock believes in their stem cell therapetic:
fiercebiotech.com/biotech/b...
And I know the statement below is coming from a new CEO of a pharma company but I find hope in his statement regarding the direction of the company:
"We have begun our journey to change medicine and to address some of the most devastating degenerative diseases, where currently we can only offer a slowed trajectory of deterioration. Our mission is to create a living medicine that can address the complex nature of these diseases, and in turn, create hope not just for treatment of symptoms, but for a cure. I cannot imagine a more exciting time to lead BlueRock,"
I hope they succeed.
". . .human embryonic stem cells. . ."
No, thanks, I will pass!!!